Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01
Among PD-L1 TPS 1-49 %, there was no significant difference in survival outcomes between the ICI-chemo group and the I-N-based therapy group. Based on the results of a subgroup analysis, ICI-chemo may be superior for treating NSCLC with a TPS of 25-49 %.
Authors
- Ryota Saito (ORCID: https://orcid.org/0000-0003-4289-7891)
- Tsukasa Hasegawa (ORCID: https://orcid.org/0000-0001-8385-9416)
- Yuichi Tambo (ORCID: https://orcid.org/0000-0002-4095-4533)
- Takehiro Tozuka (ORCID: https://orcid.org/0000-0002-3774-8915)
- Hisashi Tanaka (ORCID: https://orcid.org/0000-0003-2009-0210)
- Eisaku Miyauchi (ORCID: https://orcid.org/0000-0002-6837-6392)
- Tomonori Makiguchi (ORCID: https://orcid.org/0000-0001-9249-7904)
- Hiroshi Gyotoku (ORCID: https://orcid.org/0000-0002-5026-8078)
- Toshio Sakatani
- Yuko Tsuchiya‐Kawano
- Yosuke Kawashima (ORCID: https://orcid.org/0000-0002-9824-6572)
- Tomoaki Sonoda
- Ryosuke Tsugitomi
- Katsumi Nakatomi
- Masafumi Saiki (ORCID: https://orcid.org/0000-0001-6617-0991)
- Junji Koyama (ORCID: https://orcid.org/0000-0003-2958-7442)
- Makoto Nishio (ORCID: https://orcid.org/0000-0003-4969-4165)
- Shinsuke Ogusu
- Tomohiro Oba (ORCID: https://orcid.org/0009-0004-1500-5215)
- Keita Kudo
Institutions
- University of Fukui (JP)
- Hirosaki University (JP)
- Saga University (JP)
- NTT Medical Center (JP)
- Tohoku University Hospital (JP)
- Kanazawa University Hospital (JP)
- The Jikei University Hospital (JP)
- Nagasaki Medical Center (JP)
- Osaka Minami Medical Center (JP)
- Kitakyushu Municipal Medical Center (JP)
- Ureshino Medical Center (JP)
- Saitama Red Cross Hospital (JP)
- Yamanashi Prefectural Central Hospital (JP)
- Sendai Kousei Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- Nagasaki University (JP)
- Nagoya University (JP)
- University of Yamanashi (JP)
- Nippon Medical School (JP)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1016/j.ejca.2024.115117
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Wakayama Medical University